Pacific Edge Limited (NZE:PEB)

New Zealand flag New Zealand · Delayed Price · Currency is NZD
0.1300
-0.0030 (-2.26%)
Apr 3, 2025, 5:00 PM NZST
52.94%
Market Cap 105.55M
Revenue (ttm) 22.62M
Net Income (ttm) -28.79M
Shares Out 811.92M
EPS (ttm) -0.04
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 99,977
Average Volume 367,036
Open 0.1330
Previous Close 0.1330
Day's Range 0.1300 - 0.1350
52-Week Range 0.0500 - 0.1850
Beta 1.04
RSI 61.53
Earnings Date May 23, 2025

About Pacific Edge

Pacific Edge Limited, a cancer diagnostics company, researches, develops, and commercializes diagnostic and prognostic tools for the early detection and management of cancers in New Zealand, the United States, and internationally. It operates through two segments, Commercial and Research. The company offers Cxbladder, a genomic urine biomarker test for the detection and surveillance of bladder cancer. It also develops Cxbladder Triage, a frontline diagnostic product that helps de-intensify clinical work-up for patients with haematuria who have ... [Read more]

Industry Medical - Diagnostics & Research
Sector Healthcare
Founded 2001
Employees 114
Stock Exchange New Zealand Stock Exchange
Ticker Symbol PEB
Full Company Profile

Financial Performance

In 2023, Pacific Edge's revenue was 25.23 million, an increase of 19.95% compared to the previous year's 21.03 million. Losses were -29.54 million, 9.53% more than in 2022.

Financial Statements

News

Half Year 2025 Pacific Edge Ltd Earnings Call Transcript

Half Year 2025 Pacific Edge Ltd Earnings Call Transcript

4 months ago - GuruFocus